Quantcast

Over 2500 Patients Treated at VGH Using the MRSAid™ Photodisinfection System

February 28, 2012

Ondine Biomedical Inc. announces today that its MRSAid Photodisinfection System for nasal pathogen decolonization has successfully treated over 2,500 patients since April 2011 as a part of an infection control Quality Improvement Project being conducted at Vancouver General Hospital. This project, championed by Dr. Elizabeth Bryce, Regional Medical Director, Infection Control, Vancouver Coastal Health, is being undertaken with the objective of reducing the incidence of surgical site infections in selected surgical populations.

Vancouver, British Columbia (PRWEB) February 28, 2012

Ondine Biomedical Inc. announces today that its MRSAid Photodisinfection System for nasal pathogen decolonization has successfully treated over 2,500 patients since April 2011 as a part of an infection control Quality Improvement Project (“QIP”) being conducted at Vancouver General Hospital (VGH). This project, championed by Dr. Elizabeth Bryce, Regional Medical Director, Infection Control, Vancouver Coastal Health, is being undertaken with the objective of reducing the incidence of surgical site infections (SSIs) in selected surgical populations.

Patients with surgical site infections are 5 times more likely to be readmitted to hospital and twice as likely to die. The average SSI requires an extended hospital stay of 8 days in an acute care setting, adding millions of dollars of unnecessary costs annually to the health care system. Studies have demonstrated significant SSI reductions resulting from nasal decolonization of Staphylococcus aureus and Methicillin resistant Staphylococcus aureus (MRSA).

“Photodisinfection is a non-antibiotic approach to eradicating potentially lethal bacteria such as MRSA. Unlike antibiotics, Photodisinfection eliminates pathogens in minutes and does not generate bacterial resistance. This efficacy makes Photodisinfection ideal for hospital settings as it eliminates the need for patient compliance as it can be administered just prior to surgery,” said Carolyn Cross, Chairman and CEO of Ondine. “Our MRSAid procedure has been well received at VGH and represents a promising approach to improve patient safety in other healthcare facility settings.”

About Ondine Biomedical Inc.

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing leading edge products utilizing its patented light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development laboratories in Bothell, Washington, USA and Minneapolis, Minnesota. Please visit the Company’s website at: http://www.ondinebio.com. For further information please contact us at: Ondine Biomedical Inc. info(at)ondinebio(dot)com

###

For the original version on PRWeb visit: http://www.prweb.com/releases/prwebMRSAid_VGH/Ondine2012/prweb9232976.htm


Source: prweb



comments powered by Disqus